Top 3 innovations in diabetes management for cats

Recent advances in the treatment of diabetes in cats include notable developments such as the introduction of SGLT2 inhibitors, the availability of ultra-long-acting insulins, and the increasing use of continuous glucose monitoring (CGM) systems. These innovations significantly simplify the care of cats with diabetes for both veterinarians and cat owners.

Image of pikabum on Pixabay

Introduction

1. SGLT2 inhibitors:
   With the marketing approval of bexagliflozin tablets and velagliflozin solution, a new class of medications is available that block the reabsorption of glucose in the kidneys, thereby lowering blood glucose levels. Thanks to their oral administration, low risk of hypoglycemia, and proven efficacy, these medications could represent a viable alternative for certain cats with newly diagnosed diabetes.
2. Ultra-long-acting insulins:
   The development of ultra-long-acting insulins, such as insulin glargine U300 and insulin degludec, offers more stable blood glucose control with fewer daily injections. Although further studies are needed to determine the ideal dosage and administration frequency for cats, initial results show promising approaches to optimizing insulin management in feline diabetes.
3. Continuous glucose monitoring (CGM):
   Continuous glucose monitoring (CGM) systems allow pet owners and veterinarians to accurately monitor a cat's glucose levels over several days without frequent blood draws. This reduces stress for the animal and provides more comprehensive data for adjusting treatment. The improved accuracy of current sensors, combined with their ease of use, has made CGM a valuable tool in diabetes management.

What are SGLT2 inhibitors?

SGLT2 inhibitors, short for Sodium-glucose cotransporter-2 inhibitors, Antidiabetic drugs are a relatively new class of medications originally developed to treat type 2 diabetes in humans. Their mechanism of action is based on the targeted inhibition of the sodium-glucose cotransporter type 2 (SGLT2), which is primarily located in the kidneys.

Normally, glucose from the primary urine is reabsorbed back into the bloodstream in the proximal tubule of the kidney, with SGLT2 responsible for the majority of this reabsorption. When SGLT2 is blocked, the glucose from the primary urine can no longer be completely reabsorbed into the body. Instead, it is excreted in the urine. This effect leads to a decrease in blood glucose levels, as less glucose remains in the blood.

Besides lowering blood sugar levels, SGLT2 inhibitors have other potentially positive effects. In humans, for example, beneficial effects on body weight and blood pressure have been demonstrated, since the excretion of glucose in the urine is also associated with a loss of calories. Whether these benefits occur in a similar way in cats is still being investigated.

A key advantage of SGLT2 inhibitors is that, compared to other antidiabetic medications, they carry a lower risk of severe hypoglycemia (low blood sugar). This is because their mechanism of action is independent of insulin production. SGLT2 inhibition simply leads to increased glucose excretion, regardless of how much insulin the body produces. However, it's important to note that complete insulin dependence (for example, in insulin-dependent diabetes) can increase the risk of euglycemic ketoacidosis, as glucose is not efficiently absorbed into cells.

In veterinary medicine, SGLT2 inhibitors are currently being investigated primarily for newly diagnosed diabetes in cats, especially in animals that still possess some intrinsic insulin production. However, clinical application requires careful patient selection, as pre-existing conditions such as renal or hepatic insufficiency, as well as gastrointestinal problems, can compromise the tolerability and safety of the therapy.

In summary, SGLT2 inhibitors are an innovative treatment option for diabetes based on the blockade of a key transport mechanism in the kidneys. This inhibition leads to glucose excretion in the urine, thus lowering blood glucose levels without directly interfering with the insulin mechanism. Their use in veterinary medicine is promising but still requires intensive research and careful clinical monitoring.

Ultra-long-acting insulins

Ultra-long-acting insulins are a special type of insulin preparation characterized by a particularly long duration of action and more stable blood glucose control. Their main advantage is that they maintain a consistent insulin level for many hours, making them especially attractive as basal insulins. While traditional insulins often need to be injected several times a day and can cause significant fluctuations in blood glucose levels, ultra-long-acting insulins offer more reliable and predictable glucose control.

Development and mode of action:
The concept of ultra-long-acting insulins arose from the need to provide patients – in both human and veterinary medicine – with more comfortable and consistent blood glucose regulation. The first basal insulins, such as insulin glargine U100, already had a longer duration of action compared to short- or intermediate-acting insulins. However, ultra-long-acting insulins like insulin glargine U300 and insulin degludec go a step further: they are formulated to release insulin continuously over an even longer period (sometimes up to 24 hours or more). This is achieved through modifications to the insulin structure or through the type of suspension in which the insulin is dissolved.

Pharmacokinetics and pharmacodynamics:
The action profiles of ultra-long-acting insulins often show reduced fluctuations throughout the day. This means that insulin levels remain relatively constant, without the sharp spikes and dips seen with short-acting or mealtime insulins. A more consistent insulin release reduces the risk of hypoglycemia and can help maintain stable blood glucose levels over longer periods.

Another characteristic feature of ultra-long-acting insulins is their extended half-life. While earlier basal insulins may have been effective for only 12 to 16 hours, modern ultra-long-acting preparations can last up to 42 hours, depending on the dosage and the individual physiology of the patient. This extended duration of action means that often only a single daily injection is required, which improves patient adherence and simplifies administration for pet owners.

Advantages over conventional insulins:

1. More consistent blood sugar control:
   Ultra-long-acting insulins offer a flatter action profile, meaning that insulin levels remain relatively stable throughout the day. This helps avoid large fluctuations in blood sugar that can lead to symptoms such as drowsiness or malaise.
2. Reduced risk of hypoglycemia:
   Because ultra-long-acting insulins do not have pronounced spikes in their effect, there is a lower risk of blood sugar dropping too low. This is particularly important for sensitive patients or those with irregular eating habits.
3. Simplified therapy planning:
   With its extended duration of action, many patients (both human and animal) can manage with just one injection per day. This reduces the burden on owners and improves the quality of life for both animal and human.

Use in cats with diabetes:
The use of ultra-long-acting insulins in cats with diabetes is a promising approach, although there are still relatively few studies on this topic. Cats naturally exhibit a relatively constant insulin secretion compared to other species. Therefore, ultra-long-acting insulins, which provide a steady supply of basal insulin, could be particularly beneficial for cats. Insulin glargine U300, for example, demonstrates a longer duration of action and more stable blood glucose control in cats compared to conventional basal insulins. Insulin degludec, another ultra-long-acting preparation, also offers advantages, albeit with a slightly shorter duration of action than insulin glargine U300.

Challenges and future perspectives:
Despite their advantages, ultra-long-acting insulins, particularly in cats, present challenges. Individual responses to these preparations can vary, and an adjustment period is often necessary to determine the optimal dosage. Furthermore, factors such as comorbidities, dietary habits, and activity levels can influence insulin action. Long-term studies and further clinical experience will help determine the best use of these insulins in cats.

Ultra-long-acting insulins represent a significant advancement in the treatment of diabetes. They offer more stable blood glucose control, reduce the risk of hypoglycemia, and make therapy simpler and more convenient. For cats with diabetes, they can be a promising option, especially when a consistent and long-lasting insulin supply is required. Future studies and experience will show how these innovative insulins can best be used in practice to maximize the well-being and quality of life of affected animals.

Continuous glucose monitoring

The continuous glucose monitoring Continuous glucose monitoring (CGM) is a modern method for monitoring blood glucose levels over an extended period. It differs fundamentally from traditional blood glucose measurements, which are performed with a glucometer and a drop of blood, by continuously providing data on glucose trends, thus enabling a more complete picture of blood glucose control.

Basic principle and function:
A CGM system typically consists of three main components:

1. A sensor:
   The sensor is inserted under the skin and measures the glucose level in the interstitial fluid – a fluid located in the tissue between the body's cells. This measurement is not taken directly in the blood, but in the tissue, which results in a slight delay (usually only a few minutes) in the glucose level reading.
2. A transmitter:
   The transmitter sits on the skin's surface and is connected to the sensor. It receives the data from the sensor and transmits it wirelessly to a display device.
3. A receiver or display device:
   The measured glucose values are displayed in real time on a special reader or a smartphone app. Some systems can also issue warnings if the glucose values exceed a certain limit or fall below a critical range.

The sensor remains in the same location for an extended period (typically several days up to two weeks). During this time, it regularly records glucose levels – often every five minutes – thus providing a continuous profile of glucose trends.

Advantages of continuous glucose monitoring:

1. More comprehensive database:
   Unlike point-in-time measurements with a conventional glucometer, a CGM system provides a continuous overview of glucose fluctuations. This helps to identify trends and patterns, such as nocturnal hypoglycemia or post-meal spikes, which might go undetected with single measurements.
2. Better management of diabetes:
   Thanks to continuous data, patients and veterinarians can make more informed decisions regarding adjustments to medication dosages, diets, or insulin regimens. Early detection of problematic glucose trends also allows for timely intervention.
3. Reduced measurement volume:
   A CGM system does not require multiple finger pricks per day. Instead, the sensor continuously provides readings, resulting in less burden and discomfort for patients.
4. Warning functions:
   Many CGM systems offer alarms that warn users when their glucose level is too high or too low. These warnings can be especially valuable in preventing dangerous conditions such as hypoglycemia.

Potential applications in veterinary medicine:
Continuous glucose monitoring (CGM) systems are not only used in humans with diabetes, but are also increasingly used in veterinary medicine, particularly in cats and dogs with diabetes. The advantages are similar to those in humans:

• Minimized stress for the animal: Continuous measurement reduces the need for frequent blood draws.
• Surveillance in familiar surroundings: Pet owners can monitor their pet's glucose levels at home without constant visits to the vet. Veterinarian are necessary.
• Long-term data analysis: The data collected over several days allows the veterinarian to make a more accurate assessment of the therapy's effectiveness and possible adjustments.

Challenges and limitations:
Despite the advantages, there are also some aspects to consider when using CGM systems:

• Measurement delay: Because the measurement is taken in the interstitial fluid, the value lags behind blood glucose by about 5–15 minutes. This is particularly relevant when blood glucose levels change rapidly.
• Correct placement and durability of the sensor: The sensor must be placed in a suitable location and securely in place. Keeping the sensor in position can be particularly difficult with active animals.
• Cost: CGM systems are often more expensive to purchase and operate than conventional measurement methods, which can pose a financial hurdle for some owners.

Future prospects:
Continuous glucose monitoring (CGM) technology is constantly evolving. Newer sensors are becoming smaller, more accurate, and more user-friendly. Future generations of CGM systems could even be worn for longer periods, offer even greater accuracy, and automatically communicate with insulin pumps to regulate glucose levels in real time. Particularly in veterinary medicine, these advancements could further simplify diabetes management for both pet owners and their animals.

Continuous glucose monitoring (CGM) is an innovative approach used in both human and, increasingly, veterinary medicine. By continuously recording glucose data, it allows for more precise and individualized adjustments to diabetes treatment, reduces the stress of frequent blood draws, and improves long-term blood glucose control. CGM is a particularly promising option for cats and dogs with diabetes, offering the potential to improve their quality of life and make therapy more efficient.

Which diabetes management method is suitable for which cat?

Choosing the best treatment method for a cat with diabetes mellitus depends on a number of individual factors. Each cat has its own unique physiological and health characteristics that influence the suitability of certain treatments. The following describes the various options for treating diabetes in cats, along with their advantages and disadvantages in different clinical scenarios.

1. SGLT2 inhibitors (e.g. bexagliflozin, velagliflozin)
Especially suitable for:

• Cats with newly diagnosed diabetes: Cats that still produce sufficient insulin on their own and are not yet insulin-dependent often benefit from SGLT2 inhibitors. These medications lower blood sugar by increasing glucose excretion via the kidneys, without directly interfering with insulin metabolism.
• Cats without serious underlying diseases: Since SGLT2 inhibitors can place a certain burden on the kidneys, they are particularly suitable for cats with healthy kidney function and without serious gastrointestinal or hepatic problems.
• Owners who prefer once-daily administration: SGLT2 inhibitors are administered orally and usually only need to be given once a day. This can be particularly beneficial for owners who have difficulty administering medication more frequently.

Less suitable for:

• Cats with insulin-dependent diabetes: If the cat has little or no insulin production of its own, there is an increased risk of euglycemic ketoacidosis, as SGLT2 inhibitors do not promote cellular glucose uptake.
• Cats with kidney or liver disease: Cats with pre-existing kidney dysfunction or significant liver problems should not receive SGLT2 inhibitors, as these drugs can increase the burden on the kidneys and may cause gastrointestinal side effects.
• Seriously ill or clinically unstable cats: Cats suffering from chronic vomiting, loss of appetite, or other systemic conditions are not good candidates for this form of therapy, as the body in such conditions depends on a more stable insulin supply.

2. Ultra-long-acting insulins (e.g. insulin glargine U300, insulin degludec)
Especially suitable for:

• Cats with stable underlying disease and good general condition: Ultra-long-acting insulins offer a more consistent basal supply, which is particularly beneficial for cats with stable metabolic states.
• Cats with mild fluctuations in blood sugar levels: Since ultra-long-acting insulins have a relatively flat action profile curve, they are suitable for animals that do not show abrupt and strong fluctuations in blood sugar levels.
• Cats with established insulin therapy who had difficult control problems: In cats that were difficult to regulate with traditional insulins, switching to ultra-long-acting insulins can lead to more stable blood glucose control.
• Owners who want to inject less frequently: Ultra-long-acting insulins can often be administered once a day, which reduces stress for both the animal and the owner.

Less suitable for:

• Cats with very irregular eating habits: Cats that often eat small amounts at different times may benefit from shorter-acting insulins that are easier to adapt to irregular feeding schedules.
• Cats with pronounced hyperglycemia spikes after meals: Since ultra-long-acting insulins primarily cover basal blood glucose levels, they may be less effective in cats with high postprandial blood glucose spikes. In such cases, combination therapies or insulins with a faster onset of action are more appropriate.
• Cats with extremely short insulin action: Some cats metabolize insulin very quickly, which means that even ultra-long-acting preparations may not achieve the desired long-lasting effect.

3. Continuous glucose monitoring (CGM)
Especially suitable for:

• Cats with difficult-to-control diabetes: Cats whose blood sugar levels fluctuate significantly or who respond poorly to conventional dosage adjustments benefit from the detailed glucose curve provided by a CGM system.
• Cats whose owners want precise data: For owners who want to understand and monitor their pet's blood sugar levels accurately, a CGM system offers valuable insights and enables informed adjustments to therapy.
• Cats that are afraid of being bitten frequently: Since CGM systems do not require daily blood draws, they are particularly suitable for cats that experience stress or anxiety related to regular blood tests.
• Cats in the initial phase of insulin therapy: During the initial adjustment phase, a CGM system provides a comprehensive overview of glucose levels, enabling more precise adjustment of insulin dosage.

Less suitable for:

• Cats with a very active lifestyle: With very active or energetic cats, it can be difficult to keep the sensor securely in place.
• Cats with sensitive skin or allergies: Some animals are sensitive to the sensor or the adhesive materials, which can lead to skin irritation.
• Cats with very stable diabetes control: If a cat is already well-regulated and rarely needs adjustments, a CGM system may be unnecessary, as the added value in such cases is limited.

The choice of the appropriate treatment method should always be made on an individual basis. SGLT2 inhibitors are ideal for cats with newly diagnosed diabetes and good organ function, while ultra-long-acting insulins offer more stable long-term control. Continuous glucose monitoring (CGM) systems are particularly valuable for cats that are difficult to manage or are sensitive. The specific needs and health conditions of the cat, as well as the owner's practical considerations, should always be the primary focus when making this decision.

Overview: Methods for treating diabetes in cats

SGLT2 inhibitors

These medications block the sodium-glucose cotransporter in the kidneys, leading to increased glucose excretion in the urine. Blood sugar levels decrease without directly affecting insulin levels.

Ultra-long-acting insulins

These insulins provide a constant basal supply over a longer period. They help to keep blood sugar stable without frequent injections or large fluctuations.

Continuous glucose monitoring (CGM)

A CGM system measures the glucose level in the interstitial fluid in real time. It enables continuous monitoring of glucose levels, allowing for more precise therapy adjustments.

Frequently asked questions about diabetes management in cats

Summary Diabetes Management in Cats

Managing diabetes in cats is a comprehensive approach encompassing a variety of measures to stabilize and improve the health of cats with diabetes mellitus. At the heart of feline diabetes management is lowering and stabilizing blood glucose levels, which often requires a combination of medication, dietary adjustments, regular monitoring, and veterinary care. One of the most important pillars of feline diabetes management is the use of insulin, which can be administered in either conventional or ultra-long-acting forms. Selecting the appropriate type of insulin and determining the correct dosage are crucial for successful feline diabetes management, as these factors directly impact blood glucose levels and the cat's overall quality of life.

Another key aspect of managing diabetes in cats is the continuous monitoring of glucose levels. Modern technologies such as continuous glucose monitoring (CGM) systems allow pet owners and veterinarians to obtain detailed data on blood glucose trends. This information helps adjust therapy and assess the effectiveness of the chosen treatment plan. Managing diabetes in cats also includes regularly checking blood glucose, fructosamine levels, and other relevant parameters to ensure the disease remains under control and no complications arise.

Nutrition plays a crucial role in the management of diabetes in cats. The use of specialized diets tailored to the specific needs of diabetic cats is an essential component of this management. These diets are often low in carbohydrates and high in protein, which helps prevent postprandial blood glucose spikes and promotes insulin sensitivity. Furthermore, managing diabetes in cats can improve weight control, significantly impacting the overall health of the condition. In many cases, a successful dietary change as part of diabetes management leads to a noticeable improvement in metabolic parameters and the cat's overall well-being.

In addition to medication and dietary adjustments, managing diabetes in cats also includes addressing comorbidities. Common comorbidities such as obesity, infections, or other hormonal disorders can influence the course of diabetes. Comprehensive diabetes management in cats ensures that these comorbidities are identified and treated appropriately to maintain stable blood glucose levels and improve the cat's quality of life in the long term. A thorough examination and diagnostic workup form the basis for effective diabetes management in cats, as they allow for the development of individually tailored treatment strategies.

Managing diabetes in cats requires close cooperation between Veterinarian and pet owner. The veterinarian is responsible for the regular monitoring and adjustment of the therapy, while the pet owner plays a crucial role in the daily management of feline diabetes. This includes the correct administration of insulin, observing changes in the cat's behavior, and adhering to feeding and monitoring schedules. Successful feline diabetes management therefore depends on the education and motivation of pet owners, as they must consistently implement the measures at home.

Furthermore, feline diabetes management includes preventative and long-term care. Once blood sugar levels are stabilized, the goal of feline diabetes management is to prevent potential relapses or complications. Regular check-ups and adjustments to the treatment plan help keep diabetes under control in the long run. Feline diabetes management also focuses on minimizing stress and creating a comfortable and healthy living environment.

In summary, managing diabetes in cats is a comprehensive approach that combines drug therapies, nutritional management, continuous monitoring, treatment of comorbidities, and close collaboration between veterinarian and pet owner. Successful diabetes management in cats helps improve quality of life, prevent complications, and enable the cat to live the healthiest and most active life possible.

In the ongoing management of diabetes in cats, it is equally important to respond flexibly to changes in the cat's health. Diabetes is not a static disease but requires continuous adjustments and fine-tuning to ensure the long-term success of the therapy. In the context of feline diabetes management, this means regularly considering current research findings and new treatment options. Advances in the development of insulins, antidiabetic drugs, or monitoring systems can facilitate the management of diabetes in cats and contribute to further improving treatment.

Another key focus is observing the cat's behavior and quality of life. Successful diabetes management in cats is reflected not only in stable blood sugar levels, but also in improved vitality, a healthy weight, and an overall happier lifestyle. Pet owners should pay attention to how their cat eats, sleeps, plays, and reacts to stress as part of managing diabetes. Changes in these behaviors can indicate problems or the need for therapy adjustments at an early stage.

Furthermore, the long-term motivation of pet owners plays a key role in the management of feline diabetes. Since it is a chronic condition, the owners' commitment is crucial for the continuous implementation of necessary measures. Veterinarians should not only impart medical knowledge as part of feline diabetes management, but also provide psychological support and practical tips to facilitate daily life with a diabetic cat. A positive attitude and good communication between veterinarian and pet owner are essential factors for the success of feline diabetes management.

In conclusion, managing diabetes in cats can be understood as a dynamic process encompassing both medical and interpersonal components. With a well-considered approach that is regularly reviewed and adjusted, managing diabetes in cats allows for long-term control of the disease and an improved quality of life for the affected cat. By combining modern medicine, attentive care, and a dedicated owner, a stable condition can be achieved, enabling the cat to live a fulfilling life despite diabetes.

Further information, including: https://www.cliniciansbrief.com/article/diabetes-cats-insulin-blood-sugar-monitor